Ability Inc (CE) (ABILF) Quote

As one who agrees yay for them all, as a retired teacher special kudos for the last:

https://scontent-lax3-1.xx.fbcdn.net/v/t39.30808-6/504303855_1035121872140905_2707895258088881484_n.jpg?_nc_cat=104&ccb=1-7&_nc_sid=833d8c&_nc_ohc=9nX-zx1MrM4Q7kNvwH_P3Zn&_nc_oc=Adk-srxeQcezVhzQ5W8cL

If getting this before the eyes of AMRN legal team has 1% chance of making it to the court, I believe the best route would be via one of Amarin employees. If anybody knows an Amarin employee. Stuffs coming from external email hardly gets any attention.

Canada has approved the first spot XRP ETF. Purpose Investments received regulatory approval from the Ontario Securities Commission (OSC) to launch the Purpose XRP ETF, which will begin trading on the Toronto Stock Exchange (TSX) under the ticker XRPP on June 18, 2025

Anything for attention.

I've heard that an MD Anderson team is developing an off-the-shelf IL-21 armoured CAR-NK cell therapy that will target EGFR and IL13Ra2 https://www.cell.com/cancer-cell/abstract/S1535-6108(24)00272-1

They are also testing another off-the-shelf NK cell therapy with containing deleted o

dbergh, First many immunodeficient people wear masks to protect their lives, that first interviewer is as ignorant as you.

The 2nd again exhibits the ignorance of the one you see as smart:

Type of hormone therapy may determine whether trans men continue to menstruate

Matt Gaetz on involvement with Israel in Iran:

https://worldnews.whatfinger.com/2025/06/17/daaammmn-matt-gaetz-trump-and-iran-israel-hot-take-%f0%9f%94%a5%f0%9f%94%a5/

Oh boy. You are the wit. So who is this toxic lender you speak of. No offense but it is difficult to believe the stories that go around and around.

The amount of detail in this new program is extraordinary. You can sense the exuberance of the author.
The main takeaway is that dcvax will be the poster child of this new hugely exciting program.
There isn’t any other exciting drug on the horizon that could get people excited.That’s

The amount of detail in this new program is extraordinary. You can sense the exuberance of the author.
The main takeaway is that dcvax will be the poster child of this new hugely exciting program.
There isn’t any other exciting drug on the horizon that could get people excited.That’s

45 million shares traded price 9.2c down 7%

Robert Hipple once wrote my opinion letter

Pretty incredible Indian river is still on the filings

Henry where are my shares? Time for some legal….

But no stocks go up in this space… it’s all about selling shares

Keep adding...at this rate, there will be billions available and you'll be rich..

Rich but not a billionaire

Futures are UP. I was 100% sure they would be way down tomorrow. What? Who knew.

Just be patient...you've waited 5 years ...when there was tens of Millions... Now there's hundreds of millions!! Your time will come

No one...

You may claim 41.6.....but who enforces it.....no one...you could be waiting decades thinking JPM owes you something....you may have received it from the GSA.....but the GSA was between WMI, JPM and the FDIC and JPM came away with 600+ million.....escrows were not part of it.....would like for you t

BETTER OFF DONATING THE 100$ TO A SOUP KITCHEN

It will be interesting to see GILD's KITE-753 clinical data. The only difference between it (and KITE-363) is a reduced production time.

However, based on preclinical data, KITE-753 exhibited higher expression of both CARs and increased proportion of CCR7+/CD45RA+ T-cells* compared to

It will be interesting to see GILD's KITE-753 clinical data. The only difference between it (and KITE-363) is a reduced production time.

However, based on preclinical data, KITE-753 exhibited higher expression of both CARs and increased proportion of CCR7+/CD45RA+ T-cells* compared to

Ah, ha, ha. Then why didn't NWBO file with the FDA??? There's no material money in a UK approval. Only the U.S. delivers serious revenue and profitable pricing. If FDA considered the P3 trial legitimate, they would have encouraged NWBO to file, but.........nothing. Even if MHRA buys it, FD